公开(公告)号：US20230322900A1

公开(公告)日：2023-10-12

申请号：US18064571

申请日：2022-12-12

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Volker Schellenberger ,  Pei-Yun Chang ,  Fatbardha Varfaj ,  Sheng Ding ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P. Stemmer ,  Nathan Geething ,  John Kulman ,  Tongyao Liu ,  Garabet G. Toby ,  Haiyan Jiang ,  Robert Peters ,  Deping Wang ,  Baisong Mei

IPC: C07K14/755

CPC classification number: C07K14/755 ,  A61K38/00

Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

公开(公告)号：US11261437B2

公开(公告)日：2022-03-01

申请号：US16357153

申请日：2019-03-18

Applicant: Bioverativ Therapeutics Inc.

Inventor： Vu Phong Hong ,  Adam R. Mezo ,  Joe Salas ,  Robert Peters

IPC: C12N9/64 ,  A61K47/62 ,  A61K38/36 ,  A61K38/48 ,  A61K38/02

Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.

公开(公告)号：US10968442B2

公开(公告)日：2021-04-06

申请号：US15221420

申请日：2016-07-27

Applicant: Bioverativ Therapeutics Inc.

Inventor： Joe Salas ,  Robert Peters ,  Alan Bitonti

IPC: C12N9/64 ,  A61K38/00 ,  C07K14/745 ,  C07K16/28 ,  C07K14/755 ,  C12N9/96 ,  C07K16/18 ,  A61K39/00

Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.

公开(公告)号：US11266720B2

公开(公告)日：2022-03-08

申请号：US16270302

申请日：2019-02-07

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jennifer A. Dumont ,  Susan Low ,  Alan J. Bitonti ,  Glenn Pierce ,  Alvin Luk ,  Haiyan Jiang ,  Byron McKinney ,  Matt Ottmer ,  Jurg Sommer ,  Karen Nugent ,  Lian Li ,  Robert Peters

IPC: C07K14/755 ,  A61K38/37 ,  A61K47/64 ,  A61K47/68 ,  C07K16/46

Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20200087379A1

公开(公告)日：2020-03-19

申请号：US16521789

申请日：2019-07-25

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Volker Schellenberger ,  Pei-Yun Chang ,  Fatbardha Varfaj ,  Sheng Ding ,  Joshua Silverman ,  Chia-wei Wang ,  Benjamin Spink ,  Willem P. Stemmer ,  Nathan Geething ,  John Kulman ,  Tongyao Liu ,  Garabet G. Toby ,  Haiyan Jiang ,  Robert Peters ,  Deping Wang ,  Baisong Mei

IPC: C07K14/755

Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.